BRAIN Biotech AG / Key word(s): Miscellaneous/Patent
BRAIN Biotech AG: Additional Differentiated Genome-Editing Nuclease: BRAIN-Metagenome-Cas 01 (BMC01)
08-Dec-2021 / 14:53 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Additional Differentiated Genome-Editing Nuclease: BRAIN-Metagenome-Cas 01 (BMC01)
Zwingenberg, Germany, December 8th, 2021. BRAIN Biotech AG (“BRAIN”) is extending its proprietary genome-editing toolbox with the addition of BRAIN-Metagenome-Cas 01 (BMC01) nuclease. In comparison to the publically recognized BRAIN-Engineered Cas (BEC), the BMC01 nuclease has a differentiated protein structure and mode of action to target DNA. BMC01 has already been filed for IP protection. This additional nuclease will extend BRAIN’s proprietary genome editing competence and further enhance the overall economic potential of the platform, in case patent protection is granted.
Michael Schneiders, Head of IR & Sustainability
BRAIN Biotech AG
Investor Relations Office
End of ad hoc announcement
Information and Explanation of the Issuer to this News:
BRAIN Biotech AG (‘BRAIN’) is a leading European specialist in industrial biotechnology. As a technology provider and developer of bio-based products and solutions for nutrition, health and the environment, the company supports the biologization of industry and contributes to a more sustainable economy. BRAIN is the parent company of the BRAIN Group. Two pillars form BRAIN Group’s business: The BioScience segment includes contract research for renowned industrial partners as well as an incubator for the development of the company’s own highly innovative products. In the BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and the respective distribution.
|Company:||BRAIN Biotech AG|
|Darmstädter Straße 34-36|
|Phone:||+49 (0) 62 51 / 9331-0|
|Fax:||+49 (0) 62 51 / 9331-11|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1255619|
|End of Announcement||DGAP News Service|